Related Experiment Video
Updated: Jan 9, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Prostate Cancer: Current Status of Novel Molecular Imaging and Future Prospects
Donald C Wunsch1, Baris Turkbey1
1Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
None:
Molecular imaging has become an essential component of diagnosis, treatment planning, and monitoring in prostate cancer. Prostate-specific membrane antigen-targeted positron emission tomography is now the most widely used molecular imaging approach in prostate cancer. This mini review provides an overview of the status and prospects of novel molecular imaging in prostate cancer management. PATIENT SUMMARY: Recent years have seen improvements in scans for prostate cancer. Our mini review focuses on PSMA PET (prostate-specific membrane antigen positron emission tomography) for diagnosis of prostate cancer, especially metastatic disease, and treatment planning and monitoring. The results show that in the right setting, PSMA PET has benefits in improving outcomes for patients with prostate cancer.
Related Concept Videos
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
Imaging Studies IV: Magnetic Resonance Imaging

